Air Force reviews cancer risk in missile crews; early analyses show no excess mortality, but exposures to PCBs and benzene prompt vigilance and targeted histories.
“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."
A mid-stage trial for an experimental drug in ALS patients did not meet its main goal, with patients showing more gastrointestinal upset compared to a placebo, and differing death rates between groups. Results will be presented next year, and a long-term extension study will continue.